• Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade 

      Ree, Anne Hansen; Høye, Eirik; Esbensen, Qin Ying; Røberg Beitnes, Ann-Christin; Negård, Anne; Bernklev, Linn; Tetlie, Linn Kruse; Fretland, Åsmund Avdem; Hamre, Hanne Mari; Kersten, Christian; Hofsli, Eva; Guren, Marianne; Sorbye, Halfdan; Nilsen, Hilde; Flatmark, Kjersti; Meltzer, Sebastian (Journal article; Peer reviewed, 2024)
      The randomized METIMMOX trial (NCT03388190) examined if patients with previously untreated, unresectable abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC) might benefit from potentially immunogenic, ...
    • Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line 

      Kreutzman, Anna; Yadav, Bhagwan; Brümmendorf, Tim H.; Gjertsen, Bjørn Tore; Lee, Moon Hee; Janssen, Jeroen; Kasanen, Tiina; Koskenvesa, Perttu; Lofti, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stentoft, Jesper; Stenke, Leif; Söderlund, Stina; Udby, Lene; Richter, Johan; Hjorth-Hansen, Henrik; Mustjoki, Satu (Journal article; Peer reviewed, 2019)
      Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and ...